Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adaptive Biotechnologies Corporation    ADPT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2021 01/22/2021 01/25/2021 01/26/2021 01/27/2021 Date
67.01(c) 67.74(c) 65.51(c) 62.14(c) 54.64(c) Last
593 663 293 229 640 214 1 088 628 1 284 808 Volume
+0.22% +1.09% -3.29% -5.14% -12.07% Change
More quotes
Financials (USD)
Sales 2020 94,8 M - -
Net income 2020 -142 M - -
Net cash position 2020 509 M - -
P/E ratio 2020 -50,7x
Yield 2020 -
Sales 2021 160 M - -
Net income 2021 -164 M - -
Net cash position 2021 480 M - -
P/E ratio 2021 -46,3x
Yield 2021 -
Capitalization 7 473 M 7 473 M -
EV / Sales 2020 73,5x
EV / Sales 2021 43,8x
Nbr of Employees 453
Free-Float 94,2%
More Financials
Company
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. 
More about the company
Notations Surperformance© of Adaptive Biotechnologies Corporation
Trading Rating : Investor Rating :
More Ratings
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
01/27ADAPTIVE BIOTECHNOLOGIES CORP : Change in Directors or Principal Officers (form ..
AQ
01/11ADAPTIVE BIOTECHNOLOGIES : Partners With AstraZeneca to Use ImmunoSEQ T-MAP in O..
MT
01/11Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immun..
GL
2020Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare..
GL
2020IQVIA-Quest Diagnostics Joint Venture Q2 Form Marketing Partnership With Adap..
MT
2020ADAPTIVE BIOTECHNOLOGIES : Investor Presentation - December 2020
PU
2020Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of ..
GL
2020ADAPTIVE BIOTECHNOLOGIES : and Collaborators to Present Data from More Than 35 A..
AQ
2020ADAPTIVE BIOTECHNOLOGIES : and Collaborators to Present Data from More Than 35 A..
AQ
2020Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 ..
GL
2020ADAPTIVE BIOTECHNOLOGIES : Preliminary Data from Real-World Study Demonstrate T-..
AQ
2020Adaptive Biotechnologies Says Data Showed T-Detect Assay Better Identifies Pa..
MT
2020ADAPTIVE BIOTECHNOLOGIES : Preliminary Data from Real-World Study Demonstrate T-..
AQ
2020Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms..
GL
2020ADAPTIVE BIOTECHNOLOGIES CORP : Other Events (form 8-K)
AQ
More news
News in other languages on ADAPTIVE BIOTECHNOLOGIES CORPORATION
2020ADAPTIVE BIOTECHNOLOGIES CORPORATION : Veröffentlichung des Quartalsergebnisses
2020ADAPTIVE BIOTECHNOLOGIES CORPORATION : publication des résultats trimestriels
2020ADAPTIVE BIOTECHNOLOGIES CORPORATION : publication des résultats semestriels
2020ADAPTIVE BIOTECHNOLOGIES CORPORATION : Veröffentlichung des Halbjahresergebnisse..
More news
Analyst Recommendations on ADAPTIVE BIOTECHNOLOGIES CORPORATION
More recommendations
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | ADPT | US00650F1093 | MarketScreener
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 66,00 $
Last Close Price 54,64 $
Spread / Highest target 35,4%
Spread / Average Target 20,8%
Spread / Lowest Target -15,8%
EPS Revisions
Managers and Directors
NameTitle
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Nancy L. Hill Senior Vice President-Operations
Chad M. Cohen CFO, Principal Financial & Accounting Officer
Harlan Robins Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADAPTIVE BIOTECHNOLOGIES CORPORATION-7.59%7 473
EXACT SCIENCES CORPORATION3.29%21 763
GUARDANT HEALTH, INC.14.36%14 735
BGI GENOMICS CO., LTD.31.71%9 694
INVITAE CORPORATION14.06%9 091
IOVANCE BIOTHERAPEUTICS, INC.-8.23%6 246